Project Grant R21AG087070
- The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support a two-year research investigation through May 31, 2027. The project, titled "Investigating the Role of TDP-43 Citrullination in ALS Pathogenesis," focuses on understanding how...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This exploratory research project, scheduled for completion by May 31, 2027, investigates the roles of the deubiquitylation pathway in TDP-43 (TAR DNA-binding protein 43) pathology relevant to...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $162,000 Project Grant to Washington University, effective March 1, 2026 through February 28, 2029, under the Aging Research program (CFDA 93.866). This research project focuses on identifying and characterizing new therapy targets in TDP-43 proteinopathies—a class of neurodegenerative diseases characterized by aberrant aggregation of TAR DNA-binding protein 43. The research addresses a critical gap in understanding...
- This $1,823,353 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the Seattle Institute For Biomedical And Clinical Research aims to elucidate the molecular mechanisms by which pathological tau protein causes neurodegeneration in Alzheimer's disease (AD) and related tauopathy disorders. The research project will leverage a C. elegans model of tauopathy to investigate the functional role of nuclear speckles, membraneless organelles involved in RNA...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
- Federal Project Grant Award Summary Yale University received a $446,670 Project Grant awarded May 6, 2026, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research and development of bi-functional helical peptides designed to inhibit transactive response DNA-binding protein 43 (TDP-43) aggregation, a pathological hallmark of amylotrophic lateral...
- This Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research into the molecular interplay of sleep and neurodegeneration using the Drosophila model system. With $2.14 million provided over 11 months, the Trustees of the University of Pennsylvania will investigate how expression of the TDP-43 protein linked to neurodegenerative diseases disrupts sleep in fruit flies. Researchers will aim to define the specific glial subtypes...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $3,081,936 to the University of California, San Diego on September 12, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This Project Grant, with a completion date of June 30, 2029, supports research investigating the mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) through multimodal...
DECIPHERING TDP-43 PROTEINOPATHY: UNVEILING THE CONSEQUENCES ON OLIGODENDROCYTE DYSFUNCTION - TAR-DNA BINDING PROTEIN 43 (TDP-43) IS A NUCLEAR PROTEIN THAT HAS BEEN IMPLICATED IN SEVERAL NEURODEGENERATIVE DISEASES, INCLUDING FRONTOTEMPORAL LOBAR DEGENERATION (FTLD-TDP), AMYOTROPHIC LATERAL SCLEROSIS (ALS), AND LIMBIC-PREDOMINANT AGE-RELATED TDP-43 ENCEPHALOPATHY (LATE-NC), AMONG OTHER AGE-RELATED DEMENTIAS. THE PRESENCE OF TDP-43 AGGREGATES IN THE CYTOPLASM OF NEURONS AND GLIAL CELLS, PARTICULARLY IN OLIGODENDROCYTES (OLS), IS THE NEUROPATHOLOGICAL HALLMARK OF FTLD-TDP, ALS, AND LATE-NC. SIMILAR TO OTHER MISFOLDED PROTEINS (I.E., A-SYNUCLEIN, B-AMYLOID AND TAU), THE TRANSMISSION OF PATHOGENIC TDP-43 SPECIES BETWEEN CELLS COULD CONTRIBUTE TO DISEASE PROGRESSION IN NEURODEGENERATIVE DISEASES. OUR GROUP HAS RECENTLY SHOWN THAT PATHOLOGICAL TDP-43 DERIVED FROM FTLD-TDP BRAIN EXTRACTS CAN ACT AS PATHOGENIC SEEDS AND INDUCE THE FORMATION OF DE NOVO TDP-43 PATHOLOGY WHEN INJECTED IN THE BRAIN OF TDP-43 TRANSGENIC MICE, AND TO A LESSER EXTENT IN WILD-TYPE MICE (WT). UNDER THIS PARADIGM, TDP-43 PATHOLOGY SPREADS THROUGHOUT THE BRAIN IN A REGIONAL AND TIME-DEPENDENT MANNER. INTERESTINGLY, AS FOUND IN DISEASED HUMAN BRAINS, TDP-43 PATHOLOGY IS PRESENT IN NEURONS AND OLS. DESPITE SEVERAL STUDIES INDICATING THAT TDP-43 PATHOLOGY IN OLS IS A COMMON FEATURE OF VARIOUS NEURODEGENERATIVE DISEASES, INCLUDING AD AND FTLD-TDP, THE CONSEQUENCES OF TDP-43 PATHOLOGY IN OLS REMAINS UNKNOWN. THE PRESENT RESEARCH PROJECT AIMS TO DEVELOP IN VITRO MODELS TO STUDY THE PATHOPHYSIOLOGICAL CONSEQUENCES OF TDP-43 PATHOLOGY IN OLS AND EVALUATE THE ROLE OF OLS IN FACILITATING THE SPREAD OF TDP-43 PATHOGENIC SPECIES BETWEEN GLIAL AND NEURONAL CELLS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/8/26 | ||
| Not listed | $787.1k | 6/11/24 |